SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs planned large ASH conference booth is fueling speculation about a potential Big Pharma partnership or buyout, often linked to anticipated REGAL Phase 3 results and the delayed 80th trial event. Traders disagree over whether the booth signals strong data or a deal; neither interpretation is confirmed, and some argue the booth alone means little.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa and the FDAs decision on whether to accept it for review dominate discussion. Some traders view the filing as progress toward approval, while others point to the muted share response, uncertainty over going it alone versus a partnership or buyout, and disappointment with IZAR-1 results.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Speculation that J&J could acquire Sellas Life Sciences (SLS) is a major topic, with traders citing J&Js oncology ambitions and Sellass anticipated REGAL trial results; no deal has been confirmed. Some investors are also focused on J&Js upcoming quarterly report and debating the stocks recent performance.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

ICPs sharp rebound has traders watching whether it can break through nearby resistance and sustain a breakout; bulls welcome the renewed momentum, while skeptics expect another rejection or pullback. No specific catalyst dominates the discussion, which is focused mainly on price action and chart levels.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

Discussion centers on the S&P 500s direction amid concerns about elevated valuations, rising yields, inflation and oil prices, with some traders warning of a correction. Others favor continuing to dollar-cost average into VOO as a long-term, diversified holding and view pullbacks as buying opportunities.

Neon EVM is the EVM on Solana (currently on devnet), which enables Ethereum-based applications to have access to Solana’s scalability and liquidity without any changes to their codebase. Neon EVM is a smart contract on Solana. Solana is a fast-growing blockchain, Neon EVMs performance has been tested through multiple use cases, and the platform now includes the infrastructure and capabilities to support production level development. Notable Ethereum-based projects starting to build on Neon include Curve and Sobal (Balancer friendly fork). Neon EVM has over 200 projects in its pipeline committed to launching shortly after the launch of mainnet, including blue-chip DeFi protocols, wallets, bridges, fiat on/off ramps, infrastructure, DAO tooling, etc. The focus in the early stages will be providing the infrastructure and technical dependencies needed for a breadth of use cases to expand from EVM chains to Solana. Looking beyond mainnet, the plan is to develop interoperability with Solana smart contracts, full ecosystem compatibility, integration with additional major Ethereum tools and services, EVM support for Saga and an early grants program. Deploying on Neon EVM will onboard new users &amp; increase user activity on Aave by decreasing costs compared to Ethereum and enabling users to take advantage of Solana liquidity and access to the overall ecosystem Neon EVM is an Ethereum Virtual Machine (EVM) built into a Solana smart contract, enabling Ethereum developers to build on Solana and access its native ecosystem without changing their codebases. Neon EVM facilitates the usage of Ethereum tooling by dApp developers to scale and access unaddressed liquidity on Solana. Developers can utilize the vast majority of Ethereum dev tools

Neon EVM

NEON is drawing attention for speculative momentum trading, with traders pointing to thin liquidity, rising volume and technical breakout setups as reasons for potential sharp moves. Others remain skeptical, citing repeated pump-and-dump swings, persistent selling and token unlocks that could weigh on gains.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks shift into AI data centersanchored by a long-term Meta lease and secured-note financingis the dominant topic, alongside speculation about additional Texas deals. Bulls see the contracts and Bitcoin holdings as potential value drivers, while bears question the debt, execution risks, and the stocks weakness despite the Meta news and Bitcoin strength; the move to quarterly mining updates has also prompted concerns about transparency.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being linked by traders to the launch of confidential perpetuals powered by Hyperliquid, which makes trading positions private by default. The community is largely bullish and frames the feature as part of NEARs privacy and AI-agent story, though some traders question the rallys staying power and expect a pullback.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is drawing attention for choppy trading and a modest rebound amid broader meme-coin and altcoin activity. Bullish traders are looking for a breakout, while skeptics say it is lagging, struggling at resistance, and needs stronger volume.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

A suspected pneumonic-plague incident at a Russian research institute has revived discussion of biodefense demand and potential government attention for Emergents medical-countermeasure business. Traders are speculating about contract opportunities and short-covering, while others caution that reports remain uncertain and question whether the incident will lead to actual orders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million.
Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards byread more...

Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket

iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.read more...

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers

iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market session. The market value of their outstanding shares is at $3.8 million.
Genelux (NASDAQ:GNLX) stock moved upwards byread more...

Why iSpecimen Shares Are Surging On Friday?

iSpecimen Inc (NASDAQ: ISPC) stock is trading higher Friday after announcing a shipping overhaul that slashes transit times by up to 85%.read more...

iSpecimen Slashes Biospecimen Shipping Times by Up to 85%, Streamlining Global Research Supply Chain

iSpecimen (NASDAQ:ISPC) is making a significant operational leap, announcing a revamped logistics model that dramatically reduces the time it takes to deliver human biospecimens to researchers worldwide.

Top Pre-Market Gainers Today — ISPC, WGRX, RAYA Among Stocks That Are Soaring Before The Bell

Equity

President Donald Trump criticized Iran late night on Thursday for reportedly collecting toll from tankers trying to pass through the Strait of Hormuz.

Why Clearsign Technologies Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

Clearsign Technologies Corp (NASDAQ: CLIR) shares rose 11.3% in pre-market trading after reporting better-than-expected quarterly results. Other gainers include iSpecimen Inc, Wellgistics Health Inc...

iSpecimen Is Trending Overnight Here's Why ISPC Stock Surged 56% In The After-Hours Session

iSpecimen Inc. shares surge over 56% in after-hours trading after announcing faster shipping and expanded European sourcing, despite weak fourth-quarter results.read more...

Nasdaq Microcap Soars After Unveiling AI Tool Designed to Accelerate Medical Research

Artificial intelligence is rapidly transforming the life sciences industry, particularly in areas where speed and precision can dramatically impact research outcomes. From drug discovery to clinical data analysis, AI-powered tools are increasingly helping scientists process vast amounts of information and connect critical research resources faster than ever before. One emerging application is the use of intelligent platforms to streamline access to human biospecimens, an essential component in developing diagnostics, therapies, and medical breakthroughs.Shares of iSpecimen Inc. (NASDAQ: ...

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

iSpecimen Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ISPC 
Jesus, that meeting was a cluster.
Voting for RS remains open until end of October. 
Not much other useful information that I could understand other than there are just over 2.58m outstanding shares atm.  🥴

Ernie

$ISPC This will go down, down, down and reverse split until delisted it will scam you and take your money, stay away....

emmi ada

$ISPC if it's true that they hold 1 million solana, then this market cap should be about 50x higher

Arlen mcfarlane

$ISPC acting and looking sus…. Someone is loading. $GLND $ONCO $SLGB $SUGP  the last three were also preloaded today.

RichGalaxy

$ISPC   This POS can't hold any gains.   Bet they dilute again soon.   Usually what happens after a little after the market rally for zero reason.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ISPC iSpecimen Inc

Fundamentals

Latest ISPC News